Cargando…

A randomized controlled trial of a physiology‐guided percutaneous coronary intervention optimization strategy: Rationale and design of the TARGET FFR study

Post‐percutaneous coronary intervention (PCI) fractional flow reserve (FFR) ≥0.90 confers an improved cardiac prognosis. There are currently limited data available to determine how often it is possible to improve an angiographically acceptable but physiologically suboptimal result. A physiology‐guid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collison, Damien, McClure, John D., Berry, Colin, Oldroyd, Keith G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2020
Materias:	Trial Designs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244297/ https://www.ncbi.nlm.nih.gov/pubmed/32037592 http://dx.doi.org/10.1002/clc.23342

Ejemplares similares

Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
por: Berry, Colin, et al.
Publicado: (2013)

Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial
por: Biscaglia, Simone, et al.
Publicado: (2020)

Rationale and design of the precise percutaneous coronary intervention plan (P3) study: Prospective evaluation of a virtual computed tomography‐based percutaneous intervention planner
por: Nagumo, Sakura, et al.
Publicado: (2021)

Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease
por: Ripley, David P., et al.
Publicado: (2015)

Rationale and design of the OPTIMAL‐REPERFUSION trial: A prospective randomized multi‐center clinical trial comparing different fibrinolysis‐transfer percutaneous coronary intervention strategies in acute ST‐segment elevation myocardial infarction
por: Chen, Zhongxiu, et al.
Publicado: (2021)

Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)
por: Collison, Damien, et al.
Publicado: (2021)

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease
por: Sorbets, Emmanuel, et al.
Publicado: (2017)

Drug‐coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET‐SMALL 2
por: Gilgen, Nicole, et al.
Publicado: (2018)

Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study
por: Montarello, Nicholas J., et al.
Publicado: (2021)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial
por: Li, Yi, et al.
Publicado: (2020)

Rationale and design of a navigator‐driven remote optimization of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction
por: Blood, Alexander J., et al.
Publicado: (2019)

Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS): Rationale and design of a cluster-randomized trial()()
por: Mills, Katherine T., et al.
Publicado: (2020)

Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
por: Cannon, Christopher P., et al.
Publicado: (2016)

Rationale and Study Design of Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients with Suspected Heart Failure with Preserved Ejection Fraction
por: Kim, So Ree, et al.
Publicado: (2021)

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
por: Budoff, Matthew, et al.
Publicado: (2018)

German Cardiac Arrest Registry: rationale and design of G-CAR
por: Pöss, Janine, et al.
Publicado: (2022)

Design and rationale for the “Me & My Heart” (eMocial) study: A randomized evaluation of a new smartphone‐based support tool to increase therapy adherence of patients with acute coronary syndrome
por: Krackhardt, Florian, et al.
Publicado: (2019)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trial
por: Ducrocq, Gregory, et al.
Publicado: (2021)

The PhysioVP-AF study, a randomized controlled trial to assess the clinical benefit of physiological ventricular pacing vs. managed ventricular pacing for persistent atrial fibrillation prevention in patients with prolonged atrioventricular conduction: design and rationale
por: Pastore, Gianni, et al.
Publicado: (2023)

Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
por: Becher, Marc Ulrich, et al.
Publicado: (2021)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients
por: Zeng, Jianping, et al.
Publicado: (2021)

Design and Rationale of the PRAGUE‐12 Trial: A Large, Prospective, Randomized, Multicenter Trial That Compares Cardiac Surgery With Left Atrial Surgical Ablation With Cardiac Surgery Without Ablation in Patients With Coronary and/or Valvular Heart Disease Plus Atrial Fibrillation
por: Straka, Zbyněk, et al.
Publicado: (2012)

Design and rationale of the North Indian ST‐Segment Elevation Myocardial Infarction Registry: A prospective cohort study
por: Arora, Sameer, et al.
Publicado: (2019)

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry
por: Pereira, Naveen L., et al.
Publicado: (2021)

Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial
por: Lukhna, Kishal, et al.
Publicado: (2021)

Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI)
por: Yndigegn, Troels, et al.
Publicado: (2022)

The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease
por: Jiménez, David, et al.
Publicado: (2019)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021)

Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study()
por: Moody, William E., et al.
Publicado: (2014)

Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry
por: Berman, Adam N., et al.
Publicado: (2020)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m1ke2eoobkpmfvdgkhc4updeeo